Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • A change in federal policy on marijuana

    by
    • Optum Workers' Comp
    | Jan 30, 2018
    Tag Icon
    Medical Marijuana
    Earlier this month United States Attorney General Jeff Sessions issued a memorandum to all Department of Justice (DOJ) United States Attorneys that rescinded previous memoranda directed specifically at the enforcement of existing federal laws and prosecutorial discretion concerning marijuana. The memorandum is effective immediately. This memorandum initiates a policy change from the previous DOJ policy, which may impact marijuana enforcement at the Federal and State level. Despite this federal policy change, our guiding philosophy on the use of medical marijuana for the treatment of pain has not changed.


  • Recall of one lot of Senna Laxative 8.6 mg tablets

    by
    • Optum Workers' Comp
    | Jan 23, 2018
    Tag Icon
    recall, Laxatives
    Magno-Humphries Laboratories, Inc. announced a consumer-level recall of Basic Drugs Brand Senna Laxative (8.6 mg Sennosides) tablets. This recall is due to a complaint from a customer who found Naproxen Sodium 220 mg tablets in their bottle. At this time, no reports of injury or illness have been documented in relation to this issue.


  • Texas Division of Workers’ Compensation Moves to Close Compound Drug Loophole

    by
    • Optum Workers' Comp
    | Jan 18, 2018
    Tag Icon
    formulary, Compounded Medications
    After gathering and analyzing data on the utilization and cost components of compounded medications in Texas under their Closed Formulary, the Texas Division of Workers’ Compensation (TDWC) is poised to make a positive rule change for Texas stakeholders.


  • Primus voluntarily suspends sale of Limbrel®

    by
    • Optum Workers' Comp
    | Jan 11, 2018
    Tag Icon
    FDA
    In response to the request by the U.S. Food and Drug Administration (FDA) to recall Limbrel, Primus Pharmaceuticals announced it has voluntarily suspended promotion and sale of this medical food pending a request to meet with and receive safety data held by the FDA.